Comprehensive Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, to Be Presented at the ASCO Annual Meeting; ARIAD to Host Investor Conference Call on June 5, 2006 at 6:30 p.m. ET.
Linked as:
Extract
Comprehensive Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, to Be Presented at the ASCO Annual Meeting; ARIAD to Host Investor Conference Call on June 5, 2006 at 6:30 p.m. ET.
CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that clinical investigators from U.S. and European cancer centers will present updated data from Phase 2 and Phase 1b clinical trials of the Company's novel mTOR inhibitor, AP23573, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia, June 2...
See the full content of this document
Sponsored links
